Status:
COMPLETED
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Genetic Disorder
Turner Syndrome
Eligibility:
FEMALE
2-11 years
Phase:
PHASE4
Brief Summary
This trial is conducted in Europe. The aim of this trial is to assess whether increasing doses of somatropin (Norditropin®) can maintain the initial increase in height velocity and improve final heigh...
Eligibility Criteria
Inclusion
- Turner Syndrome
- Well documented growth rate during the previous year
- Height below the 50th percentile for the age in Dutch children
- Normal thyroid function
Exclusion
- Any endocrine or metabolic disorder
- Growth failure due to disorders of genitourinary, cardio-pulmonary, gastro-intestinal and nervous systems, nutritional/vitamins deficiencies and chondrodysplasias
- Patients with hydrocephalus
Key Trial Info
Start Date :
November 1 1989
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2003
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT01518062
Start Date
November 1 1989
End Date
September 1 2003
Last Update
January 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Alphen aan den Rijn, Netherlands